Yeedozencom Congratulates on the Approval of BeiGene’s New Anticancer Drug PARP Inhibitor-Pamiparib!
On May 7, 2021, the third new anticancer drug PARP inhibitor tislelizumab independently developed by BeiGene (generic name: Pamiparib) was officially approved by the National Medical Products Administration (NMPA) with conditions. As a registered service provider of BeiGene, Yeedozencom congratulates tislelizumab for bringing new treatment options to both platinum sensitive and platinum resistant patients with relapsed ovarian cancer.
Ovarian cancer is one of the malignant tumors that seriously threaten women's health with high malignancy and difficult treatment. In China, the annual incidence of ovarian cancer ranks the third in female reproductive system tumors and shows an increasing trend year by year, and the mortality rate ranks the first in female reproductive system malignancies①. Due to the hidden early symptoms of ovarian cancer, the lack of effective screening methods, and the rapid progression of the disease, 70% of ovarian cancer patients have been diagnosed with advanced stage②. Ovarian cancer is highly susceptible to recur after initial treatment with surgery and chemotherapy, and patient's 3-year recurrence rate is about 70%③.
In recent years, the emergence of PARP inhibitors has revolutionized the treatment of ovarian cancer. Currently, PARP inhibitors have been approved for the treatment of platinum sensitive recurrent ovarian cancer in China, and BeiGene’s PAPR inhibitor has gone further.
According to the treatments of patients with primary peritoneal cancer, fallopian tube cancer and recurrent advanced ovarian cancer who have undergone second-line or above chemotherapy and have germline BRCA (gBRCA) mutations, this PAPR inhibitor is not only effective to platinum sensitive ovarian cancer patients but also bring clinically significant and lasting remission for platinum resistant recurrent ovarian cancer patients. Studies have shown that tislelizumab has three distinct mechanisms of drug action: 1. At present, the only known PARP inhibitor④that is a non-drug pump (P-gp) substrate is expected to overcome the drug resistance problem caused by P-gp overexpression; 2. It has high membrane permeability and is easier to permeate the cell membrane to maintain the effective drug concentration in the cell membrane, thereby improving the duration of clinical remission; 3. High selectivity for PARP1 and PARP2 enzymes and high capture of PARP enzymes⑤.
The breakthrough in the medical field is not only the gospel for patients, but also the driving force for Yeedozencom to continue to provide better services to partners. Once again, I would like to express my heartfelt congratulations to BeiGene!
Yeedozencom is a provider of full life cycle management services for drug development with in-depth and compassionate attitude. On the basis of in-depth scientific knowledge and professional grasp of client’s products, the company is committed to proposing distinctive and appropriate solutions; From the client’s perspective, it can understand the difficulties of development, production, circulation and use of Chinese characteristics throughout the life cycle, so the company is full of compassionate care during the implementation of depth-based solutions. After years of accumulation, it has established and improved an integrated service platform that integrates project operation management, clinical research, registration services, biological sample analysis, data management, and statistics. It aims to help pharmaceutical companies shorten development time and provide value-added technical services to introduce products to the market as soon as possible.
① Guidelines for diagnosis and treatment of ovarian cancer (2018 edition)
②Guidelines for diagnosis and treatment of ovarian cancer (2018 edition)
③McMeekin et al 2004
④Mateo J et al., Annals of Oncol, 2019
⑤ NCI-AACR-EORTC Presentation, 2015
